Clinical trials review: crystal deposition diseases.
This review focuses on several recent clinically-related observations concerning Calcium Pyrophosphate Deposition Disease (CPPDD). Developments include new information on the epidemiology of idiopathic CPPDD in aging, on familial CPPDD, and on associated conditions that predispose to secondary CPPDD. Factors that may precipitate pseudogout, including the use of intra-articular hyaluronan and systemic G-CSF, are also discussed.
Terkeltaub
R A
RA
VA Medical Center, University of California San Diego Division of Rheumatology, 3350 La Jolla Village Drive, San Diego, CA 92161, USA.
D000368:Aged; D000375:Aging / Q000378:metabolism*; D002114:Calcinosis / Q000150:complications* / Q000175:diagnosis / Q000378:metabolism; D002130:Calcium Phosphates / Q000378:metabolism*; D002805:Chondrocalcinosis / Q000150:complications* / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D002986:Clinical Trials as Topic; D003460:Crystallization; D004164:Diphosphonates / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000150:complications* / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D011379:Prognosis; D018570:Risk Assessment
D002130:Calcium Phosphates; D004164:Diphosphonates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous